Figure 2. Cumulative mean amounts of expectorated sputum (A) and budesonide and fluticasone propionate (B) over 6-hour collection after inhalation of a dose of salmeterol/fluticasone propionate (50/500 µg via Diskus; GlaxoSmithKline, Brentford, UK) or budesonide/formoterol (400/12 µg via Turbuhaler; AstraZeneca, Gothenburg, Sweden). Mean value plots of the amount of expectorated sputum (arithmetic means) (A) and budesonide and fluticasone propionate in the expectorated sputum (percentage of estimated lung-deposited dose, geometric means) (B), cumulative over the 6-hour collection period. BUD/FORM: budesonide/formoterol; SAL/FLU: salmeterol/fluticasone propionate. Reproduced from Dalby et al. Respir Res 2009;10:104, according to the Creative Commons license BMC84.